Drug discovery and NCEs

In 2018 FDA has approved 34 new drugs which are presently in the market. Each year, CDER approves series of new drugs and biological products. Some of these products are often innovative new products that never before have been used in clinical practice. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. According to Medscape the ratio of researched drugs to eventually approved therapies at between 5,000-to-1 and 10,000-to-1. Nonetheless, if a drug manages to gain FDA approval, the cumulative direct and indirect expenses are huge.  As per estimated study performed by a well-known university, the true cost to bring a drug to market was US$2.56 billion. This figure is inclusive of just shy of $1.4 billion in average out-of-pocket costs to the drug developer, as well as $1.16 billion in time costs, which are essentially the expected returns that investors forgo while a drug is in development.

 

  • Computer Aided Drug Design (CADD)
  • Insilco Drug Discovery
  • Novel Detection Technologies and Drug Discovery
  • New Chemical Entity Exclusivity Determinations
  • Statutory and regulatory framework
  • NME versus NCE

Related Conference of Drug discovery and NCEs

November 09-10, 2020

2nd World Congress on Drug Discovery and Drug Design

Tokyo, Japan
November 09-10, 2020

21st Global Summit on Analytical and Bioanlaytical Techniques

Amsterdam, Netherlands
November 9-10, 2020

Annual Meet on Pharmacovigilance & Drug Safety

Tokyo, Japan
November 09-10, 2020

20th Medicinal & Pharmaceutical Sciences Congress

Budapest, Hungary
November 09-10 , 2020

Asia Pacific Pharmaceutics & Drug Delivery Congress

| Tokyo , Japan
November 11-12, 2020

4th World Congress on Eye and Vision

Dubai, UAE
November 16-17, 2020

World Congress on Biologics and Biosimilars

Kyoto, Japan
November 23-24, 2020

Pharmaceutics & Novel Drug Delivery Summit China

Paris, France
November 23-24, 2020

21st Middle East PharmaTech & Expo

Istanbul, Turkey
November 25-26, 2020

8th World Congress on Antibiotics, Antimicrobials & Antibiotic Resistance

Singapore City, Singapore
November 26-27, 2020

11th World Congress on Bioavailability and Bioequivalence

Istanbul, Turkey
December 02-03, 2020

2nd International Conference on Bio-Pharmaceuticals

Auckland, Newzealand
December 07-08, 2020

International Liver Congress

Dubai, UAE
December 07-08, 2020

International Conference on Biotechnology and Healthcare

Auckland, Newzealand
January 22-23, 2021

1 st Global Summit on Generic Drugs and Quality Control

Prague, Czech Republic
January 22-23, 2021

1 st World Congress on Rare Diseases & Orphan Drugs

Prague, Czech Republic
February 26-27, 2021

2nd Annual Congress on Antibiotics and Bacterial Infections

Geneva, Switzerland
March 10-11, 2021

6th Pharmaceutical Chemistry Conference

Paris, France
April 11-12, 2021

2 nd World Pharma Expo

Tokyo, Japan
April 28-29, 2021

31st Annual European Pharma Congress

London, UK
April 28-29, 2021

14th European Biosimilars Congress

London, UK
May 17-18, 2021

8th European Biopharma Congress

Prague, Czech Republic
May 19-20, 2021

36th World Pharmacology and Therapeutics Forum

Singapore, Singapore
June 07-08, 2021

2rd European Conference on Pharmacovigilance and Drug Safety

Prague, Czech Republic
July 10-11, 2021

2 nd Pharma Expo China

Tokyo, Japan
August 16-17, 2021

Global summit on Cosmetic & Reconstructive Surgery

Tokyo, Japan
August 16-17, 2021

34rd World Congress on Pharmacology

London, UK

Drug discovery and NCEs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in